IGF1 and melanoma: Together with the findings demonstrated in this study, we propose that IGFBP:VN targeting peptides are a viable therapeutic option and in combination with AKT/PI3K inhibitors could be employed for the treatment of skin malignancies, namely SCC and melanoma, in particular for patients with BRAF-mutant tumors and/or tumors overexpressing components of the IGF:VN axis.